Fradet, Yves; Bellmunt Molins, Joaquim, 1959-; Bajorin, Dean F.
(Elsevier, 2019)
Background: Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, ...